Dimerix Limited (DXB.AX)
- Previous Close
0.3400 - Open
0.3800 - Bid 0.4250 x --
- Ask 0.4300 x --
- Day's Range
0.3650 - 0.4300 - 52 Week Range
0.0520 - 0.4300 - Volume
21,770,514 - Avg. Volume
5,067,408 - Market Cap (intraday)
233.612M - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Jul 25, 2024 - Jul 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 24, 1999
- 1y Target Est
--
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.
dimerix.comRecent News: DXB.AX
Performance Overview: DXB.AX
Trailing total returns as of 5/27/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DXB.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DXB.AX
Valuation Measures
Market Cap
233.61M
Enterprise Value
220.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
136.06
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-119.20%
Return on Assets (ttm)
-63.63%
Return on Equity (ttm)
-330.96%
Revenue (ttm)
9.12M
Net Income Avi to Common (ttm)
-10.87M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
14.81M
Total Debt/Equity (mrq)
83.19%
Levered Free Cash Flow (ttm)
-6.08M
Company Insights: DXB.AX
DXB.AX does not have Company Insights